EGFR and lung carcinoma: Remarkably, lectin blotting revealed a distinct signature of enriched core fucosylation of serum proteins between 30 and 60 kDa in lung cancer (LC) patients who received multiple cycles of osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), compared to those of treatment-naive patients (Figure 1G and Figure 1—figure supplement 4).